The Cooperation of Science and Technology (COST) programme aims to increase the networking possibilities for scientists and to fund activities through the European Union (EU) scientific funding programme Horizon 2020. COST Actions, which are networks dedicated to scientific collaboration and complement national research funds, provide the opportunity to hold workshops and meetings and offer support for early-stage researchers (PhD students or postdoctoral fellows within 8 years of their PhD) through short-term scientific missions and training schools. COST Actions involve countries within Europe, but also include near neighbouring countries and international partners. Interestingly, COST Actions are not variable clinical features. Both Actions had similar structured approaches concerning clinical care, genetic testing and scientific research as well as education and training.
The development of sex and gender, and the elucidation of variant physiology, are some of the most complex topics in biology and medicine as well as in society. The main objective of the DSD and CHH COST Actions was to promote research into sex development and maturation, spanning the whole patient journey from diagnostic molecular studies to treatment, in order to improve the structured care and health of people with DSD or CHH. The Actions were designed to aid understanding of the underlying clinical heterogeneity of DSD or CHH as well as to reveal the pathophysiological commonalities between the different conditions at the molecular level. Additionally, we wanted the Actions to benefit the scientific investigation of rare diseases in the international community and to promote the formation of a European Reference Network (ERN) for better visibility of patient care.
DSDnet was built on the framework of pre-existing collaborations that took shape following the Chicago consensus in 2005 (ref.
1
) and included the DSD Working Group of the European Society for Paediatric Endocrinology, EuroDSD (funded by the 7th Framework Programme of the EU), and the international I-DSD and I-CAH registries. DSDnet was designed to promote collaboration with the project DSDLife, which was also funded within the 7th Framework Programme of the EU. The GnRH Network began earlier, in April 2012, lasting until April 2016, and was characterized by the interdisciplinary interaction of physicians and more basic scientists.
Knowledge on the prenatal sex development and pubertal maturation pathways has improved considerably in the past 20 years owing to cutting-edge research on mammalian development and elucidation of underlying genetic mechanisms (for example, see refs 2, 3 ). In parallel, descriptive clinical outcome studies have provided some insight into the long-term outcome of affected people [4] [5] [6] . However, the results of these studies are mostly inconclusive owing to the small sample sizes and broad heterogeneity of participants as closed projects, but are open to all opinion leaders from participating countries.
COST Actions provide excellent tools for scientists involved in medical research on rare diseases considering that expertise is often scattered in this area and effective networking is necessary to increase knowledge and achieve appropriate attention. From 2012 to 2017, the COST programme funded two European concerted Actions for the systematic elucidation of differences of sex development (DSD) and for congenital hypogonadotropic hypogonadism (CHH) resulting from gonadotropin-releasing hormone (GnRH) deficiency; CHH is frequently associated with anosmia (Kallmann syndrome) and has Abstract | Differences of sex development are conditions with discrepancies between chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal sex development being (almost) unaffected in most patients. To expedite progress in the care of people affected by differences of sex development and congenital hypogonadotropic hypogonadism, the European Union has funded a number of scientific networks. Two Actions of the Cooperation of Science and Technology (COST) programmes -DSDnet (BM1303) and GnRH Network (BM1105) -provided the framework for ground-breaking research and allowed the development of position papers on diagnostic procedures and special laboratory analyses as well as clinical management. Both Actions developed educational programmes to increase expertise and promote interest in this area of science and medicine. In this Perspective article, we discuss the success of the COST Actions DSDnet and GnRH Network and the European Reference Network for Rare Endocrine Conditions (Endo-ERN), and provide recommendations for future research.
well as differences in applied methodology and measures.
To provide better care for its citizens with rare and complex health issues, the EU has established the ERNs for rare conditions. In 2017, 24 ERNs were founded, encompassing the majority of the >8,000 rare conditions known today. The ERN for Rare Endocrine Conditions (Endo-ERN) is divided into eight main thematic groups, which cover all rare endocrine disorders over the lifespan. The aim of Endo-ERN is to diagnose these conditions promptly and effectively, whilst minimizing the inequities that exist for the care of affected people across the EU. Within Endo-ERN, the main thematic group 'Sex Development and Maturation' was established, stemming from previous participants of the COST Actions DSDnet and GnRH Network and whose members will build its future aims for patient care on the achieved results.
In this Perspective article, we describe the achievements of these two related COST Actions and highlight the gaps in research that were identified. Future investigations should take these considerations into account.
Achievements of the COST Actions
Clinical assessment. The clinical findings of conditions that effect sex development and maturation can be highly variable and sometimes clinically undetectable 7 . This clinical observation holds true for conditions such as complete gonadal dysgenesis (where the external phenotype is female, even if the karyotype is 46,XY) and in patients who are 46,XX and have CHH (who are unequivocally female at birth). All DSD can have associated features, with complex syndromes affecting almost all organ systems, but mainly the kidneys, heart, and peripheral and central nervous systems 4 . Therefore, any clinical investigation needs to take further developmental anomalies into account.
The clinical assessment of a patient needs to be age dependent and include an extensive whole-body examination, including the genital status. In the young child, inspection of the genitalia might reveal micropenis (<2 s.d. of normative value) and cryptorchidism. Only in DSD conditions hypospadias or further genital ambiguity will be found. At the time of puberty, in both DSD and CHH, delay of pubertal development might be a hallmark. Both of the COST Actions published recommendations on standardized clinical assessment [8] [9] [10] . For DSD, the external masculinization score 11 , which was originally designed to describe genitalia in undervirilized male infants, was modified into a more widely applicable 'external genitalia score' to cover the whole spectrum of genital appearance in both male and female infants. The tool that resulted following the modifications will become available for incorporation into online platforms such as the I-DSD for collection of standardized phenotypic data by the end of 2019.
A template for longitudinal follow-up has been created in conjunction with the I-DSD registry (M. Cools, unpublished work). Within this longitudinal follow-up tool, some questions on overall health, endocrine status, genital anatomy and function, need for psychosocial support, and gender congruence have to be considered equally important if we want to improve the quality of life of all patients with a DSD condition. A simple screen such as this might be sufficient for use in the routine clinical setting and could be followed up with more detailed assessment if indicated.
For clinical and research purposes, we considered it crucial to standardize a minimal set of time points, corresponding to important developmental milestones, at which relevant clinical data should be collected, although most patients will need medical evaluations more often than these minimums. Consensus was reached on the following time points: assessment at diagnosis and at ages 4 years and 8 years allows for documentation of psychological developmental milestones and gender development, presence of associated symptoms and growth patterns, and ensures the provision of timely and adequate information to the child and their parents. At the start and termination of puberty, and at the transition to adult care, documenting the outcome of pubertal development and the physical and mental status was considered paramount. Various age intervals were identified in adulthood, each with specific requirements. At ages 18-25 years, independence is gained and new intimate relationships are formed. At ages 25-40 years, issues around fertility and forming a family might dominate discussions with patients. By contrast, at age intervals 40-60 years and 60-80 years, the long-term effects of hormonal treatment (or lack thereof) and comorbidities might become apparent (M. Cools, unpublished work and ref.
10
). Several experts of the GnRH Network COST Action conducted or reviewed multicentre trials that highlight the need for improved management of affected patients and the importance of a structured and lifelong clinical assessment. In particular, Dwyer et al. conducted the first and only randomized clinical trial on the induction of puberty, testicular growth and fertility in treatment-naive young adults with GnRH deficiency 12 . They evaluated the fertility outcomes by sperm count and surrogate markers during a 24-month pulsatile GnRH administration versus 4 months of recombinant human folliclestimulating hormone (rhFSH) pretreatment followed by 24 months of GnRH therapy. They demonstrated the superiority of rhFSH pretreatment on both surrogate markers (including testicular volume) and sperm count. A subsequent review of the GnRH Network experts confirmed the superiority of rhFSH pretreatment before the combined gonadotropin or pulsatile GnRH administration for the induction of pubertal development and testicular growth in patients with severe GnRH deficiency 13 . In addition, the GnRH COST action evaluated the psychosexual development of 101 men with CHH 14 . The study revealed that male patients with CHH frequently experience psychosexual problems that hamper intimate relationships and the initiation of sexual activity. These persistent effects cause considerable distress and are not ameliorated by longterm treatment. Therefore, psychosexual assessment followed by appropriate psychological support and treatment is warranted in these patients.
Genetics. Both the DSDnet and GnRH
Network Actions stratified a diagnostic approach to elucidate the underlying genetic anomaly and published position and consensus papers on this topic 8, 15 . In people with DSD, the determination of a karyotype is still seen as an initial mandatory step, as numerical or structural chromosomal abnormalities account for a considerable subset of DSD conditions. However, many patients with DSD or CHH might have an unaffected chromosomal complement, and so detailed studies for molecular genetic conditions are needed.
Both Actions favoured collaboration between basic scientists and clinicians to understand the molecular aetiology and develop collaborative bioinformatics tools to rapidly aid the identification of novel genetic causes. Collaborations within the GnRH Network led to the discovery of several novel candidate genes underlying CHH [16] [17] [18] [19] [20] . The collaborative efforts in DSDnet led to the identification of variants in a new gene associated with 46,XY DSD 21 and mutations in a nuclear factor, NR2F2, which cause a novel syndromic form of 46,XX DSD 22 . We predict that it is highly likely that other new genes causing DSD will be identified through the DSDnet and Endo-ERN collaborative network in the near future.
In 2015, the first European Consensus Statement on CHH was published 8 . The consensus document covers aspects related to the pathogenesis, diagnosis and treatment of this rare condition. This document is the result of the interaction between the members of the clinical and genetic working groups of the GnRH Network. Specifically, the experts documented the existence of particular phenotype-genotype correlations (for example, CHH and hearing loss are particularly frequent among patients with SOX10, IL17RD or CHD7 gene defects) and provided recommendations for improved treatment of patients with CHH, with the early and continuous examination of outcomes, including future fertility.
Despite these important advances, the majority of patients, particularly those with 46,XY conditions that effect sex development and maturation (excluding primary errors of the endocrine system), do not have a molecular diagnosis. The accurate interpretation of high-throughput sequencing datasets is challenging in the clinical setting. The challenges arise in part owing to emerging evidence that these conditions might be caused by variants in many different genes, and the prevalence of variants in a single gene could be very low 23 . To build robust evidence to support causality, sharing genomic data between research groups and developing informative animal and cellular models are required.
To improve the way in which we share genomic data, DSDnet established a secure platform for sharing data between research groups, called 'SDgeneMatch' 24 . A 'match' occurs when two users of the system are found with a variant in the same gene. Matches are reported to the two researchers that supplied the relevant gene identifier. Reporting of matches will be done behind the password-protected environment of SDgeneMatch, ensuring only the users that originally uploaded the match will be able to learn the matching gene name. Although other gene matching systems do exist, SDgeneMatch is currently specific for DSD, and the DSD research community will be actively encouraged to submit data into the system. Matching data in this way can accelerate gene and/or variant discovery in the field and encourage collaboration with groups working on animal and/or cellular model systems in order to provide evidence of causality as well as to explore the molecular pathways involved. In addition, data matching will lead to a more accurate molecular diagnosis for DSD (Box 1).
Endocrine assessment. Rare endocrine conditions, such as DSD and CHH, are often genetically determined and feature hormonal imbalances as the result of divergent endocrine pathways. However, in childhood and puberty, endocrine abnormalities can be difficult to detect and tend to be highly variable depending on the age and developmental stage of the affected person 7 . Therefore, the COST Actions primarily aimed to identify appropriate laboratory determinations useful in the complex differential diagnostics of DSD and CHH. The secondary aim was to develop guidelines for the usefulness of specific laboratory analyses and testing conditions. These guidelines were directed towards the implementation of clinical standards for diagnosis and appropriate treatment of DSD and CHH to achieve the best outcomes for patients, regardless of where patients are investigated or managed 8, [25] [26] [27] . In a position paper by Kulle et al., all forms of DSD were summarized and, for each condition, the required hormonal work-up and suitable analytical techniques were described 25 . The main recommendations were to support the appropriate use of both immunoassay-based and mass spectrometry-based methods for the diagnosis and monitoring of DSD; use both serum and urine and appropriate matrices for the analysis of steroids; and laboratories should aim to participate in activities of peer comparison 25 . The next step for the harmonization of laboratory assessments relates to the important plasma and/or serum analyte 17-hydroxyprogesterone, which is a key marker in the diagnosis of congenital adrenal hyperplasia 28 . Hereto, we conducted, in collaboration with colleagues in China, Singapore and Australia, a worldwide survey on mass spectrometric determinations of this analyte. This collaboration resulted in a publication 28 indicating that, although mass spectrometry-based methods are similar in many facets, they are highly disparate, leading to heterogeneous reference values over the whole lifespan. Consequently, five recommendations have been developed to support the continued improvement of analysis of plasma or serum 17-hydroxyprogesterone by mass spectrometry 28 .
Education and training. Both COST Actions used the specific tools of the COST programme to provide training and education to early-stage researchers. Specifically, they developed the Action websites DSDNet and CHUV, and coordinated and integrated the activities of the other working groups. Some of the scientific efforts were translated into public dissemination through a series of articles (full list at DSDNet (dissemination) and CHUV (publications)), meetings (six working group meetings and/or workshops for DSDnet, the last one in combination with GNRH Network) and position papers 8, 10, 15, 25, 29 . The COST Actions used part of their funds to provide training for eligible young scientists and organized three training schools. The three training schools were set up to provide multidisciplinary training to young professionals (trainees) and encourage ongoing activity in the fields of DSD and CHH. These interactive meetings, each of which included ~30 trainees and 10 trainers, were designed to cover important topics relevant to science and clinical work.
Box 1 | Steps to optimize diagnosis of DSD
• We need to be able to differentiate the diagnosis of differences of sex development (DSD) conditions, especially of 46,XY, with a stratified approach using both biomarkers and nextgeneration sequencing technologies • We need to be able to differentiate congenital hypogonadotropic hypogonadism versus constitutional delay of growth and puberty • We need to identify novel biomarkers for diagnosis and assessment of the utility of refining the phenotype to enhance genetic testing • We need to further understand the role of environmental factors (such as endocrine disruptors, nutrition and exercise) on sex development and delayed puberty or early onset central hypogonadism and later outcomes • We need to develop personalized counselling of patients using results obtained by nextgeneration sequencing technologies • We need to improve genetic counselling (monogenic versus oligogenic forms, estimation of variations of undefined significance, and extremely variable penetrance and expressivity of heterozygous variants)
The key long-term aim of each training school was to encourage the trainees to be involved in and to improve the national and international networking capabilities of interdisciplinary research for breakthrough science. To achieve the key long-term aim within DSDnet, for example, trainees were encouraged to participate in the I-DSD registry, apply for grants and fellowships in the field of DSD and become active members of the Endo-ERN. A report that analysed, through specific surveys, the success and subsequent outcome of the training schools for the trainees was published in 2019 (ref.
30
).
Briefly, the high rate of positive responses from trainees demonstrates the success of the training school model that the DSDnet has adopted, and shows that the majority of the participating trainees are still active in the DSD field. These positive results justify the continuation of this form of postgraduate multidisciplinary training.
Another educational tool is the organization of the short-term scientific missions (STSMs). The STSMs were aimed at supporting individual mobility in order to share knowledge and technology that might not be available in the home institution, strengthening the existing networks in the field and fostering collaborations by allowing scientists to visit an institution or laboratory in another participating COST country. There were three grant periods throughout the duration of the COST Actions. The overall comparison between the number of STSMs during COST Action DSDnet (n = 10 between 2015 and 2017; 3.33 per year) and COST Action GnRH Network (n = 23 between 2013 and 2016; 5.75 per year) of our partners in the Endo-ERN demonstrates some differences in missions between the two actions. One possible explanation could be the increased participation of basic scientists in GnRH Network, who are willing and able to perform an STSM in another laboratory site. By contrast, the participation of clinical scientists in such exchanges could be hampered by their clinical duties.
Improving patient care. We need to promote and optimize patient management and care for the complex conditions involved in sex development and maturation (Box 2). DSDnet intended to understand the current practice and research priorities amongst professionals and patients. These objectives were primarily achieved through a series of web-based surveys that targeted paediatric endocrinologists, providers of psychosocial support, and paediatric surgeons and urologists 31, 32 . The survey aimed at paediatric endocrinologists revealed that 40% of the DSD centres had a multidisciplinary team available at initial presentation 31 . Half of the centres reported that they share their data in a multicentre registry. In addition, the survey revealed that local access to specialist biochemical and genetic tests influenced the diagnostic process, and that detailed molecular genetic testing was becoming routine. Approximately one-third of regions surveyed had seen the development of clinical networks. Expert centres were increasingly disseminating knowledge to non-expert centres through arranging local clinical meetings, case discussion and regional DSD clinics. Evidence of conferences and training days and e-learning tools was also reported. Survey participants suggested a number of research priorities, which highlights, among other requirements, the need for more studies that aim to understand and improve the quality of life.
In this survey, paediatric endocrinologists were asked to rate their research priorities in order of importance 31 ; see TaBle 1 for a summary. The most frequently indicated topics were development of DSD-specific health-related quality of life measures and interventions that will improve quality of life, gender development and fundamental research on basic mechanisms underlying DSD and DSD-related diseases 31 . The survey among providers of psychosocial care investigated access to and modalities of psychosocial care, organization and practice 32 . The survey revealed that psychosocial care is predominantly provided to parents and focuses on coping and acceptance of the diagnosis and the atypical genitalia, decisions on genital surgery, disclosure and education. Adult patients have less access to counselling than parents, children and adolescents 32 . Given that this age group in particular requires support for coping with a range of DSD-related health and psychosexual issues [33] [34] [35] [36] , improving the accessibility of psychosocial counselling for adults should be prioritized. Sexological counselling for men and women with DSD hardly received attention in the survey; however, there is a compelling need for the development of sex therapies focused on sexual problems experienced by men and women with DSD. Providers of psychosocial care have a wide range of training backgrounds; this variety and the absence of an overarching professional body hinder professional development 32 . The assessment of patient needs was emphasized by both the DSDnet and GnRH Network Actions. A DSDnet face-to-face workshop held for 33 patients, their relatives and professionals included one or more patients and a health-care professional from the same centre from eight different European countries 37 . The focus of this workshop was to understand the needs and perceptions of patients and parents who had recent experience of health care within the centres represented in DSDnet. In addition, there were five professionals who ran the breakout sessions and ten people who represented support groups. The background of the professionals included endocrinology, psychology, nursing, sociology and urology. Topics discussed included experiences around diagnosis, childhood and experiences of young people, experiences of transition to adult services, the I-DSD registry, future research areas, obtaining consent in practice and patient 618 | oCToBeR 2019 | volume 15
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Box 2 | Steps to optimize patient management
• There is a need to increase patient participation in an international registry and to investigate and overcome the hurdles preventing such participation • The continuous assessment of outcomes, patient satisfaction and quality of care is needed -Need to understand the effect of delayed diagnosis and/or inappropriate treatment on psychological outcome -Patients need targeted psychosocial interventions and enhanced peer-to-peer support • The development of clinical benchmarks based on outcomes reported by clinicians, patients and parents is required • Greater involvement of patients and parents in setting research priorities will aid patient management • There is a need to identify specialized care centres -Assessment of the quality of care delivered by the specialist centre -Need for professional education and development of the multidisciplinary care team within the specialist centre • A greater awareness of the availability of diagnostic tests in accredited laboratories is required • Adherence to treatment and transition to adult services -Interventions to promote adherence and transitional care from paediatric to adult services • Development of patients' associations in several countries education, and information resources. All attendees acknowledged the constructive nature of the workshop. The collaborative model of the workshop offered valuable ideas to improve clinical services, perform patient-oriented research and optimize the development and use of registries 32 . The model that was used for these workshops could be extended in the future to engage in a separate setting with human rights and intersex advocacy organizations.
GnRH Network included patients' perspectives in their annual meetings 38 .
The patients' point of view formed an important component of these meetings, thus providing a novel opportunity for health-care professionals to identify particular gaps in patient care. In particular, the GnRH Action conducted the first survey evaluating the unmet needs in 105 adult males with CHH 38 . The study was publicized online via a closed (private) CHH social media group (Facebook), CHH forum (chat room), a clinical trials registry and the COST Action website. The survey revealed that male patients with CHH often have long gaps in care and still struggle with considerable psychosocial sequelae that are often unrecognized by the health-care community. A specific component within the GnRH Network's webpage was created and currently represents a friendly and functional tool for researchers, physicians and patients involved in the area of CHH in the EU. Researchers and physicians are able to connect to other members of the consortium through this webpage in order to share their data and establish productive collaborations. In addition, educational materials co-created by expert clinicians and patients, which have been translated into different languages, were developed and included in the webpage 39 . The addition of educational material will help patients and their families to understand all forms of GnRH deficiency, find centres of excellence to optimize their treatment, learn how to prepare for a visit with their doctor and discover research centres where they can participate in studies. This additional resource also means that patients and their families can browse online resources and support groups and find answers to their questions. This process might serve as a roadmap for creating patient education materials for other rare diseases.
Future research needs
Future research priorities can be identified through the achievements of the international networks as they incorporated a broad variety of professionals with clinical and basic science backgrounds. In addition, the international networks also involved patients and patient advocates as important opinion leaders.
Needs that can be addressed by the systematic and standardized data collection strategies proposed by the COST Actions include the development of treatment protocols that improve clinical outcomes and quality of life 40 . Furthermore, the collection and analysis of long-term post-surgery data, the effect of living with atypical genitalia, gender well-being and the overall health of individuals who have a DSD or CHH through the transition phase and at older ages need to be investigated (Box 3). A major challenge that needs addressing is that all these data, which are often the result of medical management that took place several decades ago, need to be interpreted in the societal and medical context of today. Research priorities will have to be set in discussion with clinicians and patient advocates, who are currently involved as European Patient Advocacy Groups in the Endo-ERN, acting as a partnership between patients, researchers and health-care providers. The common objective of research into this area is the improvement of clinical care and long-term outcomes.
As increasing numbers of patients with rare, and presumably genetically determined complex conditions, undergo genomic sequencing 41 , there is increasing concern about the ability to robustly establish causality for novel therapeutic candidates. Thus, basic research is equally as important and complements clinical science, as it minimizes misidentification of condition-related genes and an erroneous interpretation that would have severe consequences for patients and their families. Some forms of DSD and CHH are very rare and providing statistical evidence in favour of causality might not be possible despite the availability of data-sharing platforms.
An important additional tool for the identification of novel therapeutic candidates is the study of mouse models. Variants in a human gene associated with sex development and maturation can be modelled in the mouse in a number of ways. First, a null (complete loss of function) allele can be generated rapidly using CRISPRCas9 genome-editing technology -such a mouse variant immediately answers the question of whether the gene is required for normal sex development in a related mammal and conditional gene deletion approaches can also be performed 42, 43 . Secondly, specific sequence variants (for example, point variants) can also be introduced by genome editing 44 . This facility volume 15 | oCToBeR 2019 | 619 NATuRe RevIeWS | ENDocRiNoLogy P e r s P e c t i v e s Survey based on 78 respondents (63% response rate). When asked whether "Fundamental research is priority in DSD research", 86% of responders said yes, while 14% said no. When asked if "Molecular diagnosis is a main goal for fundamental research", 78% said yes, while 22% said no. a Sum: the total of points each field was given.
is important if the human variant does not represent a loss-of-function allele. Thirdly, gain-of-function might also be modelled by overexpression transgenesis 45 . The power of mouse models lies in the ability of researchers to perform examination of gene function, in a whole organismal context, in a mammalian model that shares many fundamental genetic pathways with humans. Mouse models also permit the study of the role of genetic background, which can have profound effects on penetrance and expressivity.
Nevertheless, the drawback to mouse models is that they are not human. Differences between mouse and human reproductive biology are widespread. Another complementary tool for the analysis of novel gene variants involves the use of cellular reprogramming technology, where candidate variants can be introduced into cell lines and/or induced pluripotent stem cells and their effect on the reprogramming or derivation of somatic cells of either the testis or ovary can be assessed. These approaches can be combined with genome-editing techniques to permit the generation of cell lines in which rare variants are 'corrected' such that a common allele is now present, thereby acting as a powerful control.
The biology and genetics of a patient's response to treatment, the influence of a patient's genome on long-term outcomes and the potential development of comorbidities are poorly understood. In part, this lack of understanding reflects the need for us to further investigate the genetic aetiology of variant sex development and maturation in general, in addition to the absence of follow-up studies combined with deep phenotyping and harmonization of laboratory data. Thus, the collection of detailed and standardized phenotypic data over the longer term should be performed in parallel to the compilation of genetic data to improve our understanding of the wider health implications of existing and novel genetic variants in the field. Such studies will be made possible following the development of a European Registry for Rare Endocrine Conditions and by increasing the awareness of and participation in existing registries 40 .
The diagnostic pathway in patients with variant sex development and maturation requires close interlinking between the clinical, biochemical and genetic diagnostic work-up. The relevance of genetic testing for the differential diagnosis between CHH and constitutional delays of growth and puberty, a frequent para-physiological condition confounding the early recognition of patients with GnRH deficiency, was recently reported by a group of experts of the GnRH Action 46 . However, currently, healthcare systems across Europe differ greatly in structure and funding (see European Reference Networks on Rare Conditions for examples). These disparities result in heterogeneous clinical and laboratory resources in the respective countries. In addition, and although highly desirable in such a complex field, interaction with research laboratories is often not possible due to lack of access and funding as well as ethical implications of data security measures. Consequently, diagnosis and management depend heavily on local or national pathways. With regards to reasonable hormonal determinations, highly qualified and specialized laboratories across European countries are required. This task is currently promoted by the ERNs and is due to be established in EU countries. Close interactions between patients and their families and health-care providers as well as valid research can improve medical care for people with conditions affecting sex development and maturation, and diminish the discomfort in society and the medical community towards gender variances 28 (Box 4).
Conclusion
The development of two COST ActionsDSDnet and GnRH Network -led to key advances in the field of sex development and maturation thanks to the involvement of experts from different disciplines and affected individuals. However, there is a clear need to continue the momentum in this rapidly evolving field with studies following on from this large body of work. Such studies would fill the gaps that still hamper basic understanding of the physiological and pathophysiological events and their inclusion into optimal patient management. Furthermore, ongoing progress must be made in science to aid other public and political stakeholders in their decision-making regarding various aspects of dealing with diversity of sex in society and culture.
These advancements might be possible through the development of Endo-ERN, which is a structure without time limits that includes the clinical participants and stakeholders from the affected community within the political EU. Endo-ERN will make expert patient care visible and allow for clinical management progress. However, there are several issues that need to be addressed. First, the ERNs currently do not 620 | oCToBeR 2019 | volume 15
Box 3 | Need for randomized clinical trials
• Randomized clinical trials for the induction of puberty: need to identify the best treatment and timing of treatment initiation both in differences of sex development and in congenital hypogonadotropic hypogonadism • Need for multicentre randomized clinical trials:
-In patients without minipuberty and micropenis at birth -In patients with delayed puberty (start of treatment at 14-18 years) -To assess gonadotropins versus testosterone on fertility outcome in congenital hypogonadotropic hypogonadism • long-term studies evaluating neonatal gonadotropin treatment to optimize fertility, gonadotropin treatment during adolescence versus adulthood for fertility optimization, and the role of prior androgen treatments on fertility outcomes • optimal approach to the induction of fertility in male and female patients Box 4 | Needs for acceptance of variant sex development
• Integration of basic science into differences of sex development-related research to explain the broad range of variabilities in sex development and maturation • Development of defined prospective outcome studies of medical interventions and their omission for the better understanding of patient needs in the medical context • Guarantee psychosexual assessment and psychological support for patients with differences of sex development and congenital hypogonadotropic hypogonadism • Focusing on gender well-being rather than gender incongruence • Defining personalized sex development as a human rights issue and reconciliation of opposing views on appropriate management • Interactive multidisciplinary and interdisciplinary approaches of natural sciences and humanities for the better understanding of the socio-cultural context • Integration of a broad range of stakeholders into public information and education of both professionals and the lay public allow non-EU participants since the ERNs have to adhere to the EU legal frameworks of health care. Second, one of the main purposes of the COST Actions, namely the networking of basic and clinical scientists, is restricted in ERNs because pure research institutions are not part of the ERNs at this time. Therefore, further possibilities that allow both clinical and translational science to be part of networking activities need to be sought. One possibility is the inclusion of ERNs and researchers into the European Joint Programme Cofund, which was just positively reviewed and granted as a collaborative project in the European funding programme Horizon 2020 to promote research, education and training in rare diseases. Furthermore, connection to clinicians and translational and basic scientists outside of the EU has to be sought and respective co-funding programmes for international collaborative research need to be developed.
